Thrombopoietin-receptor agonists

Current Opinion in Hematology

Volumn 19, Issue 5, 2012, Pages 392-398

  Basciano, Paul A ^a   Bussel, James B ^a,b  

^a Department of Medicine   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

fibrosis; hepatitis C; immune thrombocytopenia; MYH9; thrombopoietin

Indexed keywords

ELTROMBOPAG; ROMIPLOSTIM; THROMBOPOIETIN RECEPTOR; THROMBOPOIETIN RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTERY DISEASE; ARTHRALGIA; BILIRUBIN BLOOD LEVEL; CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HEPATITIS C; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NAUSEA; NONHUMAN; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; THROMBOEMBOLISM; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; VOMITING; WISKOTT ALDRICH SYNDROME;

BENZOATES; HUMANS; HYDRAZINES; PYRAZOLES; QUALITY OF LIFE; RECEPTORS, FC; RECEPTORS, THROMBOPOIETIN; RECOMBINANT FUSION PROTEINS; THROMBOCYTOPENIA; THROMBOPOIETIN;

EID: 84865430616     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e328356e909     Document Type: Review

References (60)

1. Ballem PJ, Segal GM, Stratton JR, et al. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest 1987; 80:33-40. (Pubitemid 17097513)
2. McMillan R. Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura. Semin Hematol 2000; 37:239-248. (Pubitemid 30612902)
3. McMillan R, Wang L, Tomer A, et al. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 2004; 103:1364-1369. (Pubitemid 38168649)
4. Chang M, Nakagawa PA, Williams SA, et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 2003; 102:887-895. (Pubitemid 36917780)
5. Nugent D, McMillan R, Nichol JL, Slichter SJ. Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production. Br J Haematol 2009; 146:585-596.
6. Cines DB, McKenzie SE, Siegel DL. Mechanisms of action of therapeutics in idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 2003; 25 (Suppl 1):S52-S56. (Pubitemid 37517920)
7. Broudy VC, Lin NL. AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine 2004; 25:52-60. (Pubitemid 38018897)
8. Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 2004; 76:628-638. (Pubitemid 39601552)
9. Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesisstimulating protein, for chronic ITP. N Engl J Med 2006; 355:1672-1681. (Pubitemid 44583957)
10. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008; 371:395-403. (Pubitemid 351181334)
11. Kuter DJ, Rummel M, Boccia R, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 2010; 363:1889-1899.
12. Shirasugi Y, Ando K, Miyazaki K, et al. Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial. Int J Hematol 2011; 94:71-80.
13. Elalfy MS, Abdelmaksoud AA, Eltonbary KY. Romiplostim in children with chronic refractory ITP: randomized placebo controlled study. Ann Hematol 2011; 90:1341-1344.
14. Bussel JB, Buchanan GR, Nugent DJ, et al. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood 2011; 118:28-36.
15. Khellaf M, Michel M, Quittet P, et al. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. Blood 2011; 118:4338-4345.
16. Bussel JB, Kuter DJ, Pullarkat V, et al. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009; 113:2161-2171.
17. George JN, Mathias SD, Go RS, et al. Improved quality of life for romiplostimtreated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. Br J Haematol 2009; 144:409-415.
18. Sanz MA, Aledort L, Mathias SD, et al. Analysis of EQ-5D scores from two phase 3 clinical trials of romiplostim in the treatment of immune thrombocytopenia (ITP). Value Health 2011; 14:90-96.
19. Michel M, te Boekhorst PA, Janssens A, et al. Reduced corticosteroid use in adult patients with primary immune thrombocytopenia receiving romiplostim. Hematology 2011; 16:274-277.
20. Klaassen RJ, Mathias SD, Buchanan G, et al. Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP). Pediatr Blood Cancer 2012; 58:395-398.
21. Duffy KJ, Shaw AN, Delorme E, et al. Identification of a pharmacophore for thrombopoietic activity of small, nonpeptidyl molecules. Discovery and optimization of salicylaldehyde thiosemicarbazone thrombopoietin mimics. J Med Chem 2002; 45:3573-3575. (Pubitemid 34856096)
22. Erickson-Miller CL, DeLorme E, Tian SS, et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol 2005; 33:85-93. (Pubitemid 40127647)
23. Jenkins JM, Williams D, Deng Y, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007; 109:4739-4741. (Pubitemid 46827766)
24. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007; 357:2237-2247. (Pubitemid 350190754)
25. Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373:641-648.
26. Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011; 377:393-402.
27. Psaila B, Bussel JB, LindenMD, et al. In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. Blood 2012; 119:4066-4072.
28. Deng Y, Madatian A, Wire MB, et al. Metabolism and disposition of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist, in healthy human subjects. Drug Metab Dispos 2011; 39:1734-1746.
29. Takeuchi K, Sugiura T, Umeda S, et al. Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent. Drug Metab Dispos 2011; 39:1088-1096.
30. Bauman JW, Vincent CT, Peng B, et al. Effect of hepatic or renal impairment on eltrombopag pharmacokinetics. J Clin Pharmacol 2011; 51:739-750.
31. Gibiansky E, Zhang J, Williams D, et al. Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura. J Clin Pharmacol 2011; 51:842-856.
32. Tomiyama Y, Miyakawa Y, Okamato S, et al. A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia (ITP). J Thromb Haemost 2012; 10: 799-806.
33. Matthys G, Park JW, McGuire S, et al. Clinical pharmacokinetics, platelet response, and safety of eltrombopag at supratherapeutic doses of up to 200mg once daily in healthy volunteers. J Clin Pharmacol 2011; 51:301-308.
34. Zeng Y, Duan X, Xu J, Ni X. TPO receptor agonist for chronic idiopathic thrombocytopenic purpura. Cochrane Database Syst Rev 2011(7): CD008235.
35. Catala-Lopez F, Corrales I, Martin-Serrano G, et al. Risk of thromboembolism treated with thrombopoietin receptor agonists in adult patients with thrombocytopenia: systematic review and meta-analysis of randomized controlled trials. Med Clin (Barc) 2012. [Epub ahead of print]
36. Kuter DJ, Mufti GJ, Bain BJ, et al. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood 2009; 114:3748-3756.
37. Boiocchi L, Orazi A, Ghanima W, et al. Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities. Mod Pathol 2012; 25:65-74.
38. Olnes MJ, Scheinberg P, Calvo K, et al. Eltrombopag can stimulate trilineage hematopoiesis with transfusion independence in patients with refractory severe aplastic anemia: results from a phase II trial. ASH Annual Meeting Abstracts 2011; 118:54
39. Ghanima W, Junker P, Hasselbalch HC, et al. Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents. Br J Haematol 2011; 155:248-255.
40. Brynes RK, Orazi A, Verma S, et al. Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenic purpura (ITP) treated with eltrombopag: data from the EXTEND study. ASH Annual Meeting Abstracts 2011; 118:528.
41. Kantarjian H, Giles F, List A, et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer 2007; 109:1705-1714. (Pubitemid 46668530)
42. Kantarjian H, Fenaux P, Sekeres MA, et al. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol 2010; 28:437-444.
43. Sekeres MA, Kantarjian H, Fenaux P, et al. Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. Cancer 2011; 117:992-1000.
44. Kantarjian HM, Giles FJ, Greenberg PL, et al. Phase 2 study of romiplostim in patients with low-risk or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood 2010; 116:3163-3170.
45. Mavroudi I, Pyrovolaki K, Pavlaki K, et al. Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome. Leuk Res 2011; 35:323-328.
46. McHutchison JG, Dusheiko G, Shiffman ML, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007; 357:2227-2236. (Pubitemid 350190753)
47. Dusheiko G, Afdhal NH, Giannini E, et al. Final results of open-label treatment with eltrombopag during ENABLE 1: a study of eltrombopag as an adjunct for antiviral treatment of hepatitis Cvirus associated with thrombocytopenia. ASH Annual Meeting Abstracts 2011; 118:2232.
48. Visco C, Ruggeri M, Laura Evangelista M, et al. Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia. Blood 2008; 111:1110-1116. (Pubitemid 351213389)
49. D'Arena G, Cascavilla N. Romiplostim for chronic lymphocytic leukemiaassociated immune thrombocytopenia. Leuk Lymphoma 2011; 52:701-704.
50. Sinisalo M, Sankelo M, Itala-Remes M. Thrombopoietin receptor agonists can be used temporarily with patients suffering from refractory chronic lymphocytic leukemia-associated immunologic thrombocytopenia. Leuk Lymphoma 2011; 52:724-725.
51. Pecci A, Gresele P, Klersy C, et al. Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations. Blood 2010; 116:5832-5837.
52. Leon C, Evert K, Dombrowski F, et al. Romiplostim administration shows reduced megakaryocyte response-capacity and increased myelofibrosis in a mouse model of MYH9-RD. Blood 2012; 119:3333-3341.
53. Bussel JB, Frelinger AL, III, Mitchell WB, et al. Platelet function and response to thrombopoietin mimetics in Wiskott-Aldrich syndrome/X-linked thrombocytopenia. ASH Annual Meeting Abstracts 2010; 116:1429.
54. Parameswaran R, Soff GA. Romiplostim in a case series of chemotherapyinduced thrombocytopenia. ASH Annual Meeting Abstracts 2011; 118: 1170.
55. Demeter J, Istenes I, Fodor A, et al. Efficacy of romiplostim in the treatment of chemotherapy induced thrombocytopenia (CIT) in a patient with mantle cell lymphoma. Pathol Oncol Res 2011; 17:141-143.
56. Liesveld JL, Phillips GL, II, Becker MW, et al. Phase I study of eltrombopag for promoting thrombopoiesis in patients undergoing stem cell transplantation after total body irradiation. ASH Annual Meeting Abstracts 2011; 118:3295.
57. Ruiz-Delgado GJ, Lutz-Presno J, Ruiz-Arguelles GJ. Romiplostin may revert the thrombocytopenia in graft-versus-host disease. Hematology 2011; 16: 108-109.
58. O'Donovan EM, Rezvani K, Sargent J, et al. Thrombopoietic agonists show efficacy in ITP related to allogeneic stem cell transplantation. ASH Annual Meeting Abstracts 2011; 118:3292.
59. Calmettes C, Vigouroux S, Tabrizi R, Milpied N. Romiplostim [AMG531, Nplate(R)] for secondary failure of platelet recovery after allogeneic stem-cell transplantation. ASH Annual Meeting Abstracts 2011; 118:1994.
60. Ojeda E, Garcia-Marco JA, Navarro B, et al. Use of romiplostim to facilitate platelet engraftment in allogeneic hematopoietic transplantation. ASH Annual Meeting Abstracts 2011; 118:1947.